Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
177Lutetium-miltuximab by GlyTherix for Bladder Cancer: Likelihood of Approval
177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
177Lutetium-miltuximab by GlyTherix for Urethral Cancer: Likelihood of Approval
177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Urethral Cancer. According to GlobalData, Phase I...
177Lutetium-miltuximab by GlyTherix for Ureter Cancer: Likelihood of Approval
177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Ureter Cancer. According to GlobalData, Phase I...
177Lutetium-miltuximab by GlyTherix for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According to...
177Lutetium-miltuximab by GlyTherix for Metastatic Prostate Cancer: Likelihood of Approval
177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData, Phase...
177Lutetium-miltuximab by GlyTherix for Metastatic Pancreatic Cancer: Likelihood of Approval
177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase...